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Abstract
A 52 year old female presented with a Siewert's type III gastroesophageal junction (GEJ) adenocarcinoma treated
with neoadjuvant chemotherapy, laparoscopic-robotic total gastrectomy, and adjuvant chemoradiation.
Keywords: Gastroesophageal junction; Laparoscopic gastrectomy
Abbreviations:
GEJ: Gastroesophageal Junction; FISH: Fluorescence In Situ
Hybridization; CT: Computed Tomography; PET: Positron Emission
Tomography; EUS: Endoscopic Ultrasound
Case Description
A 52 year old female presented with a Siewert’s type III
gastroesophageal junction (GEJ) adenocarcinoma treated with
neoadjuvant chemotherapy, laparoscopic-robotic total gastrectomy,
and adjuvant chemoradiation. Presenting symptoms were a 6 week
history of worsening belching and abdominal bloating.
 The patient was first evaluated by gastroenterology and underwent
upper endoscopy with findings significant for a 1 cm nodule at the GEJ
with thickening of the gastric cardia and associated erosions.  
Biopsies were taken of the gastric body and antrum, and the nodule.
Biopsies of the body and antrum returned as benign. Biopsy of the
nodule returned as well-differentiated adenocarcinoma, HER2/neu
was positive by fluorescence in situ hybridization (FISH).  Computed
tomography (CT) scans of the chest, abdomen, and pelvis revealed
mild gastric wall thickening without evidence of metastatic disease.
Positron emission tomography (PET) scan identified two areas of
hypermetabolic foci along the greater curvature of the stomach in
addition to activity at the GEJ without evidence of metastatic disease
(Figure 1A and B).
Endoscopic ultrasound (EUS) and diagnostic laparoscopy were
performed. EUS revealed invasion into the adventitia of the cardia
without evidence of surrounding adenopathy, staging T3N0.
Diagnostic laparoscopy and port placement were completed
concurrently.
At the time of surgery, the stomach was found to be edematous at
the cardia and fundus including the area of the lesser curvature with
concern for linitis plastica extending into the distal esophagus (Figure
2). There was no evidence of peritoneal disease at the time of
laparoscopy.
Additionally, genetic testing was performed as part of her initial
work up and evaluation secondary to her family history of breast and
rectal cancer with no clinically significant mutations identified.
Figure 1: Preoperative PET scan. Preoperative PET scan with area of
hypermetabolism along the greater curvature of the stomach as
noted by the white arrow.
Figure 2: Diagnostic laparoscopy. Laparoscopic image taken at the
time of diagnostic laparoscopy. L: Liver, S: Stomach, arrow denotes
area along the lesser curvature which appeared thickened and
injected with concern for linitis plastica-type change.
She received 6 cycles of neoadjuvant chemotherapy with mDCF and
trastuzumab [1]. Four weeks after the completion of her neoadjuvant
therapy, she underwent a laparoscopic, robotic-assisted total
gastrectomy with roux-en-Y esophagojejunostomy, D2
lymphadenectomy and jejunostomy tube placement.  The majority of
the dissection was completed robotically and the anastomosis was
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hand-sewn using the robot (Figure 3). Pathology revealed grade 3,
poorly-differentiated adenocarcinoma centered at the cardia and
extending to the GEJ and fundus, surgical margins were negative, 6/16
lymph nodes were positive, and HER2/neu was negative. Final staging
was ypT3N2, Stage IIIB. Final pathology did not reveal any evidence of
chemotherapy response with all viable tumor noted. The postoperative
course was complicated by a slow return to oral intake. Tube feeds were
continued for 8 weeks postoperatively following which the jejunostomy
tube was removed. Secondary to the poor pathologic response to
neoadjuvant chemotherapy, it was decided to treat postoperatively with
5-fluorouracal-based chemoradiation (4500 cGy over 5 weeks) as per
McDonald protocol, which she completed without further delay [2].
Figure 3: Robotic hand-sewn esophagojejunal anastomosis. Hand-
sewn robotic-assisted esophageal to jejunal anastomosis. L: Liver, E:
Proximal esophageal margin, J: Jejunum.
Ten months postoperatively the patient developed difficulty with
oral intake and was admitted to the hospital several times for presumed
partial small bowel obstruction. Ultimately, parenteral nutrition was
initiated. CT scanning of the abdomen and pelvis revealed dilated
small bowel loops in the epigastrium, bilateral hydronephrosis and
ascites.  Diagnostic laparoscopy was performed and revealed diffuse
peritoneal disease. Biopsy confirmed metastatic adenocarcinoma.
Jejunostomy tube was replaced. After multidisciplinary discussion, the
patient elected to enroll in Hospice and succumbed to her disease
shortly thereafter.  
Discussion
The described case represented an unfortunate circumstance of
locally advanced gastric cancer progressing to metastatic disease
despite best medical therapy. It highlights the complex presentation of
gastric cancer patients and the importance of multidisciplinary
discussion in their management.
The classification of GEJ cancers was first described by Siewert in
2000 [3]. The classification system allows for uniform description of
these tumors in addition to guiding recommended surgical therapies.
Classically, type I tumors are recommended for esophagectomy and
type III tumors are recommended for total gastrectomy [4]. Type II
tumors can be treated with either surgical approach with the goal to
obtain adequate lymphadenectomy and negative surgical margins. In
their original series, postoperative mortality was higher for the
esophagectomy group suggesting a preference for gastrectomy when
technically feasible [3].
There remains some debate in the published literature regarding the
management of Siewert’s type III GEJ tumors. Type III tumors are
known to be larger at presentation and more infiltrative when
compared to type II tumors [5,6]. The median 5 year survival for type
III tumors is 51-63% [7-9]. In a 2007 series by Barbour et al. 52% of
patients with type III tumors were treated with gastrectomy with
limited esophagectomy while the remaining type III patients were
treated with extended esophagectomy.[10] The median esophageal
margin length was 2.5 cm for type III tumors compared to 3.5 cm for
type 1 and 4.0 for type II. Margin length of >3.8 cm was found to be an
independent predictor of overall survival, similar to the number of
positive nodes, AJCC T classification, and poorly differentiated
tumors. Margins were not predictive of survival in patients with
greater than 6 positive lymph nodes.[10] Similar studies have
supported wide margin resection [11]. However, in a 2015 series from
the US Gastric Cancer Collaborative, the importance of gastric cancer
resection margins was re-examined. Proximal margin length was not
found to be predictive of increased local recurrence or overall survival.
Further, while R1 resection was associated with increased nodal
disease burden, it was not found to be associated with increased local
recurrence or decreased overall survival. The recommendations of this
series were to limit wide margin resection, particularly if it required
extended esophageal resection [12].
Kneuertz et al. evaluated the type of surgery for Siewert’s type II and
III tumors in relation to overall survival [7]. The majority of patients in
this study presented with locally advanced disease and were treated
neoadjuvantly with chemoradiation. Seventy-five percent of patients
with type II tumors were treated with esophagectomy, while 88% of
patients with type III tumors were treated with gastrectomy. The type
of surgery was not found to be predictive of R0 resection rates or
overall survival. The only factor found to be associated with improved
overall survival was extended lymphadenectomy. Similar results were
previously reported by Barbour et al. in 2007 with adequate staging, as
defined by >/= 15 lymph nodes, in T2 or greater tumors to be an
independent prognostic factor of improved survival [13].
Siewert’s type II/III tumors have been shown to have a better
response to neoadjuvant chemoradiation with increased rates of
complete pathologic response. However, while there was no individual
differences between the classifications, when Siewert’s type I tumors
are compared to II/III tumors, type II/III tumors are found to have an
overall increased rate of local recurrence [14]. Patterns of recurrence
have been shown to differ between the groups with disseminated
recurrence being the most common for Siewert’s type III lesions [15].
In this case we utilized a minimally invasive approach with both
laparoscopic and robotic resection. Several studies have demonstrated
the safety and oncologic efficacy of minimally invasive resection for
advanced gastric cancer [16-18]. In a recent meta-analysis comparing
open verses minimally invasive laparoscopic total gastrectomy,
minimally invasive total gastrectomy was found to have equivalent
lymph node yield and mortality with shorter time to first flatus,
decreased hospital stay, and fewer complications [16]. The data for
robotic gastric cancer resections is still evolving. However, it has been
shown to be equivalent to laparoscopic resections with increased
operative time but lower intraoperative blood loss and improved
lymph node retrieval [19].
Conclusion
In conclusion, the current literature would support that the type
of surgery selected is not an independent predictor of outcome. But
rather, the adequacy of oncologic resection focusing on R0 resection
and, more importantly, adequate lymphadenectomy appear to improve
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patient outcome. As this case demonstrates, despite best surgical
management including negative-margin resection and extended
lymphadenectomy, gastroesophageal junction adenocarcinoma
remains an aggressive disease with increased rates of local and distant
recurrence.
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